Last update 14 Dec 2025
Suzhou Yasheng Pharmaceutical Co., Ltd.

Suzhou Yasheng Pharmaceutical Co., Ltd.

Subsidiary Company|2016|Jiangsu Sheng, China

Overview

Tags

Neoplasms
Hemic and Lymphatic Diseases
Immune System Diseases
Small molecule drug
Molecular glue
Chemical drugs

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms10
Hemic and Lymphatic Diseases6
Immune System Diseases6
Endocrinology and Metabolic Disease4
Nervous System Diseases2
Infectious Diseases1
Top 5 Drug TypeCount
Small molecule drug8
Chemical drugs1
Molecular glue1
Top 5 TargetCount
KRAS G12D(GTPase KRas G12D)2
ALK x FAK x ROS11
CK1α x GSPT1 x IKZF1 x IKZF2 x IKZF3 x N-Myc x c-Myc1
Bcl-2(Apoptosis regulator Bcl-2)1
Bcr-Abl T315I x c-Kit1

Related

10
Drugs associated with Suzhou Yasheng Pharmaceutical Co., Ltd.
Lisaftoclax
Target
Bcl-2
Mechanism
Bcl-2 inhibitors
Active Org.
Suzhou Yasheng Pharmaceutical Co., Ltd.Suzhou Yasheng Pharmaceutical Co., Ltd. [+3]
Originator Org.
Suzhou Yasheng Pharmaceutical Co., Ltd.Suzhou Yasheng Pharmaceutical Co., Ltd.
Active Indication
Chronic Lymphocytic Leukemia [+27]
Inactive Indication
Advanced Malignant Solid Neoplasm [+4]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date08 Jul 2025
Olverembatinib
Target
Bcr-Abl T315I x c-Kit
Mechanism
Bcr-Abl T315I inhibitors [+1]
Active Org.
Ascentage Pharma Group International Co., Ltd.Ascentage Pharma Group International Co., Ltd. [+3]
Originator Org.
Guangzhou Shunjian Biomedical Technology Co., Ltd.Guangzhou Shunjian Biomedical Technology Co., Ltd.
Active Indication
Aggressive-Phase Chronic Myelocytic Leukemia [+11]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date24 Nov 2021
APG-2449
Target
ALK x FAK x ROS1
Mechanism
ALK inhibitors [+2]
Active Org.
Ascentage Pharma Group, Inc. [+6]
Originator Org.
Jiangsu Yasheng Pharmaceutical Development Co. Ltd.Jiangsu Yasheng Pharmaceutical Development Co. Ltd.
Active Indication
Non-Small Cell Lung Cancer [+8]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
18
Clinical Trials associated with Suzhou Yasheng Pharmaceutical Co., Ltd.
CTR20254307
/ RecruitingPhase 1
奥雷巴替尼片在肝功能正常和肝功能不全受试者中的药代动力学研究
[Translation] Pharmacokinetic studies of olaribatibin tablets in subjects with normal and impaired liver function
NCT06182969
/ RecruitingPhase 1/2
A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of APG-2575 in Patients with Mild-to-moderate Systemic Lupus Erythematosus.
NCT05701306
/ RecruitingPhase 1
A Phase I Clinical Study of APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
100 Clinical Results associated with Suzhou Yasheng Pharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Suzhou Yasheng Pharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Suzhou Yasheng Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Suzhou Yasheng Pharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
3
1
Preclinical
Phase 1
2
2
Phase 2
Approved
2
2
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free